{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:36:37Z","timestamp":1790984197611,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13555-025-01394-2","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:14:53Z","timestamp":1744809293000},"page":"1239-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Edoardo","family":"Mortato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Buononato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Primavera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1394_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8:437.","journal-title":"Signal Transduct Target Ther"},{"key":"1394_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann B, Lesley R, Blom B, et al. Novel P19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715\u201325.","journal-title":"Immunity"},{"key":"1394_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1394_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317.","journal-title":"J Am Acad Dermatol"},{"key":"1394_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. Br J Dermatol. 2021;185:1146\u201359.","journal-title":"Br J Dermatol"},{"key":"1394_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5021\/ad.2022.34.3.173","volume":"34","author":"S Choi","year":"2022","unstructured":"Choi S, Oh S, Yoon H-S. Association between short-term PASI90 achievement and drug survival of biologics in patients with psoriasis. Ann Dermatol. 2022;34:173.","journal-title":"Ann Dermatol"},{"key":"1394_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11: e049822.","journal-title":"BMJ Open"},{"key":"1394_CR9","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018Clinical Super Response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37:2016\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.3390\/jcm13175175","volume":"13","author":"L Marcelli","year":"2024","unstructured":"Marcelli L, Belcastro A, Talamonti M, et al. Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience. J Clin Med. 2024;13:5175.","journal-title":"J Clin Med"},{"key":"1394_CR11","doi-asserted-by":"crossref","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol [Internet]. 2022;157. Cited 7 Dec 2024.","DOI":"10.23736\/S2784-8671.21.07132-2"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14712598.2023.2194485","volume":"23","author":"M Galluzzo","year":"2023","unstructured":"Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23:371\u201381.","journal-title":"Expert Opin Biol Ther"},{"key":"1394_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai T-F, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE Trial. Br J Dermatol. 2018;178:114\u201323.","journal-title":"Br J Dermatol"},{"key":"1394_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/PTT.S372262","volume":"12","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis Targets Ther. 2022;12:205\u201312.","journal-title":"Psoriasis Targets Ther"},{"key":"1394_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.289","volume":"4","author":"M Galluzzo","year":"2024","unstructured":"Galluzzo M, Marcelli L, Fico A, Bianchi L, Talamonti M. Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: a case series. Skin Health Dis. 2024;4: e289.","journal-title":"Skin Health Dis"},{"key":"1394_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-023-00893-4","volume":"13","author":"J Hugo","year":"2023","unstructured":"Hugo J, Kojanova M, Turkova B, et al. Long-term efficacy, safety, and drug survival of guselkumab in patients with psoriasis: real-world data from the Czech Republic BIOREP Registry. Dermatol Ther. 2023;13:787\u2013801.","journal-title":"Dermatol Ther"},{"key":"1394_CR17","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/jcm9072170","volume":"9","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9:2170.","journal-title":"J Clin Med"},{"issue":"4","key":"1394_CR18","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/jdv.19599","volume":"38","author":"K Javaid","year":"2024","unstructured":"Javaid K, Andruszka C. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: an analysis with considerations for future studies. J Eur Acad Dermatol Venereol. 2024;38(4):e302\u20133.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01394-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:29:51Z","timestamp":1745688591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01394-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco Galluzzo and Marina Talamonti declare to have acted as speakers and\/or consultants for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis and Sanofi, outside the submitted work. Luca Bianchi declares to have acted as a speaker and\/or consultant for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis, Pfizer, Sanofi and UCB outside the submitted work. Lorenzo Marcelli declares no conflict of interests. Anna Balato has served as consultant and\/or has received fees from: AbbVie, Almirall, Amgen,Boehringer Ingelheim, BMS, Leo-Pharma, Eli-Lilly, Johnson & Johnson, Novartis, Sanofi and UCB, outside the submitted work. Dario Buononato declares no conflict of interests. Nicoletta Bernardini and Nevena Skroza declare to have acted as speakers and\/or consultants for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis and UCB, outside the submitted work. Giacomo Caldarola has received consulting fees, honoraria and support for attending meetings from Abbvie, Eli-Lilly, Johnson & Johnson, UCB, Novartis and Leopharma. Clara De Simone has received support for consulting fees, honoraria and support for attending meetings from Abbvie, Eli-Lilly, Johnson & Johnson, UCB, Leopharma, Sanofi, Almirall, Boehringer Ingelheim and Bristol Myer Squibb. Eleonora De Luca declares no conflict of interests. Francesco Loconsole declares no conflict of interests. Edoardo Mortato declares no conflict of interests. Felice Primavera declares no conflict of interests. Viviana Lora declares no conflict of interests. Claudio Bonifati declares no conflict of interests. Matteo Megna declares to have acted as speakers and\/or consultants for AbbVie, Amgen, Almirall, Eli-Lilly, Janssen-Cilag, LeoPharma, Novartis, Eli Lilly, UCB, outside the submitted work. Luca Potestio e Nello Tommasino declares no conflict of interests. Serena Lembo declares to have acted as speakers and\/or consultants for Abbvie, Eli Lilly, Sanofi, Novartis, Janssen, LeoPharma outside the submitted work. Annunziata Raimondo declares to have acted as a speaker and\/or consultant for Almirall, Janssen, Pfizer, Abbvie, and Novartis outside the submitted work. Maria Esposito has served as speaker\/consultant for Abbvie, Amgen, Almirall, Eli Lilly, Janssen, Leopharma, Novartis, Pfizer, Sanofi, UCB. Maria Concetta Fargnoli has served as consultant\/advisor, received speaker honoraria and\/or grants, and\/or is investigator for AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, LEO Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma, Takeda. Anna Campanati has served as speaker\/consultant for Abbvie, Almirall, Amgen, BMS, Difa-Cooper, Eli Lilly, Janssen, Leopharma, Mertz, Novartis, Pfizer, Sanofi, UCB. Tommaso Bianchelli has served as speaker\/consultant for Abbvie, Almirall, Amgen, Janssen, Novartis, Pfizer, Sanofi, UCB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Anna Campanati is an Editorial Board member of Dermatology and Therapy. Anna Campanati was not involved in the selection of peer reviewers for the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the 1975 Declaration of Helsinki ethical standards. According to Italian law, formal ethical committee approval is not required for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}